Edition:
United Kingdom

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

0.34USD
5:22pm GMT
Change (% chg)

$0.04 (+12.33%)
Prev Close
$0.30
Open
$0.33
Day's High
$0.36
Day's Low
$0.33
Volume
117,489
Avg. Vol
28,530
52-wk High
$2.75
52-wk Low
$0.29

Latest Key Developments (Source: Significant Developments)

Cancer Genetics Reports Q3 Loss Per Share $0.31
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q3 LOSS PER SHARE $0.31.Q3 REVENUE FELL 26 PERCENT TO $5.9 MILLION.  Full Article

Cancer Genetics Enters Strategic Partnership With Genecast Biotechnology
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS ENTERS STRATEGIC PARTNERSHIP WITH GENECAST BIOTECHNOLOGY TO COMMERCIALIZE TISSUE OF ORIGIN TEST IN CHINA.CANCER GENETICS INC - AGREEMENT WITH GENECAST BIOTECHNOLOGY TO MARKET, DISTRIBUTE AND SELL TISSUE OF ORIGIN (TOO) TEST IN CHINA.  Full Article

Cancer Genetics And Cellaria LLC Announced New Collaboration
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS INC - CO AND CELLARIA, LLC ANNOUNCED A NEW COLLABORATION TO DEVELOP EXTENSIVE PRECISION MEDICINE TOOLS AND PLATFORM TECHNOLOGIES.  Full Article

Cancer Genetics’ Unique Tissue Of Origin Test (Too®) Receives Special FDA 510(K) Clearance
Monday, 16 Apr 2018 

April 16 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS’ UNIQUE TISSUE OF ORIGIN TEST (TOO®) RECEIVES SPECIAL FDA 510(K) CLEARANCE.CANCER GENETICS’ UNIQUE TISSUE OF ORIGIN TEST (TOO®) RECEIVES SPECIAL FDA 510(K) CLEARANCE.  Full Article

Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM.CANCER GENETICS INC - ‍RECEIVED $1.1 MILLION IN NET CASH PROCEEDS FROM TRANSFER OF TAX CREDITS.  Full Article

Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Stonepine Capital Management::STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING.  Full Article

Cancer Genetics Receives New York State Approval For Oncomine Dx Target Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NEW YORK STATE APPROVAL FOR FDA-APPROVED ONCOMINE DX TARGET TEST BY THERMO FISHER SCIENTIFIC.  Full Article

Cancer Genetics Q3 loss per share $0.15
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cancer Genetics Inc :Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies.Q3 loss per share $0.15.Q3 revenue $8.0 million versus i/b/e/s view $7.9 million.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Cancer genetics inc - ‍integration of vivopharm acquisition is on-track and will deliver a full quarter of results and additional revenue in q4 of 2017​.  Full Article